Prathyusha Duraibabu Net Worth

Prathyusha Duraibabu biography

Prathyusha Duraibabu serves as Vice President - Finance of the Company. she has served as the Company’s Vice President, Finance since March 2019. Ms. Duraibabu has over 20 years of experience in financial operations, accounting, audit and compliance. Prior to joining the Company, Ms. Duraibabu served as Corporate Controller, Senior Director at Pacific Biosciences of California, Inc., a publicly-traded commercial biotech company, from June 2010 to March 2019. At Pacific Biosciences, she was responsible for worldwide accounting, compliance and consolidated reporting of seven entities. Ms. Duraibabu received a Bachelors of Accounting from Oxford Brookes University in Oxford, United Kingdom and an M.B.A. from San Jose State University. Ms. Duraibabu is a Certified Public Accountant in the State of California.

How old is Prathyusha Duraibabu?

Prathyusha Duraibabu is 40, she's been the Vice President - Finance of Sangamo Therapeutics Inc since 2019. There are 18 older and no younger executives at Sangamo Therapeutics Inc. The oldest executive at Sangamo Therapeutics Inc is H. Stewart Parker, 64, who is the Independent Director.

What's Prathyusha Duraibabu's mailing address?

Prathyusha's mailing address filed with the SEC is C/O SANGAMO THERAPEUTICS, INC., 501 CANAL BLVD., RICHMOND, CA, 94084.

Insiders trading at Sangamo Therapeutics Inc

Over the last 24 years, insiders at Sangamo Therapeutics Inc have traded over $87,969,621 worth of Sangamo Therapeutics Inc stock and bought 3,434,008 units worth $48,483,268 . The most active insiders traders include Capital Management, L.P.Ra ..., Le Roy C Kopp, and Inc.Biogen Ma Inc. Biogen. On average, Sangamo Therapeutics Inc executives and independent directors trade stock every 21 days with the average trade being worth of $40,671. The most recent stock trade was executed by Inc.Biogen Ma Inc. Biogen on 26 September 2023, trading 6,000,000 units of SGMO stock currently worth $3,000,000.

What does Sangamo Therapeutics Inc do?

for sangamo therapeutics, science is a means to develop new medicines with the potential to transform the lives of patients living with serious genetic diseases. our scientists are leaders in the discovery, research and development of technologies enabling gene-based therapeutic development. currently we are conducting clinical trials, including the first ever in vivo human genome editing studies. to learn more about sangamo, visit the our website at www.sangamo.com.

Sangamo Therapeutics Inc executives and stock owners

Sangamo Therapeutics Inc executives and other stock owners filed with the SEC include:

• Alexander Macrae,
  President, Chief Executive Officer, Director
• Sung Lee,
  Chief Financial Officer, Executive Vice President
• Gary Loeb,
  Executive Vice President, Chief Compliance Officer, General Counsel, Secretary
• Dr. Alexander D. Macrae Ch.B, M.B., MRCP, Ph.D.,
  CEO, Pres & Director
• R. Andrew Ramelmeier,
  Executive Vice President - Technical Operations
• Dr. R. Andrew Ramelmeier Ph.D.,
  Exec. VP of Technical Operations
• D. Mark McClung,
  Exec. VP & COO
• James Meyers,
  Independent Director
• H. Stewart Parker,
  Independent Director
• Joseph Zakrzewski,
  Independent Director
• Robert Carey,
  Independent Director
• Saira Ramasastry,
  Independent Director
• Karen Smith,
  Independent Director
• McDavid Stilwell,
  IR Contact Officer
• John Markels,
  Independent Director
• Kenneth Hillan,
  Director
• Prathyusha Duraibabu,
  Vice President - Finance
• D. Mark McClung,
  Executive Vice President, Chief Business Officer
• Scott B. Willoughby,
  Sr. VP, Gen. Counsel & Corp. Sec.
• Prathyusha Duraibabu CPA, M.B.A.,
  Sr. VP, CFO & Principal Accounting Officer
• Dr. Jason D. Fontenot Ph.D.,
  Sr. VP & Chief Scientific Officer
• Prathyusha Duraibabu,
  VP of Fin., Principal Accounting Officer & Principal Financial Officer
• Dr. Duncan McKay,
  Sr. VP & GM of Europe
• Heather Erickson,
  Chief of Staff
• Dr. Nathalie Dubois-Stringfellow,
  Sr. VP of Product Devel. & Management
• Whitney Jones,
  Sr. VP & Chief People Officer
• Aron Feingold,
  Head of Corp. Communications & Investor Relations Officer
• Dr. Jason Fontenot Ph.D.,
  Sr. VP & Chief Scientific Officer
• Stephen George Dilly,
  Director
• Paul B Cleveland,
  Director
• Henry Ward Wolff,
  Director
• Steven J Mento,
  Director
• William R Ringo,
  Director
• Geoffrey Nichol,
  Executive Vice President, R&D
• Curt A. Iii Herberts,
  Sr.VP & Chief Business Officer
• Dale G Ando,
  VP, Therapeutic Dev. & CMO
• Edward R. Conner,
  Sr. VP & Chief Medical Officer
• Thomas G Wiggans,
  Director
• William G Gerber,
  Director
• Roger Jeffs,
  Director
• Heather D Turner,
  EVP, General Counsel & Sec.
• Robert J. Schott,
  SVP, Head of Development
• Stephane Boissel,
  EVP, Corp. Strategy
• Kathy Yi,
  EVP & Chief Financial Officer
• Margaret Liu,
  Director
• Michael C Wood,
  Director
• Greg Zante,
  Sr Dir., Finance and Admin
• Le Roy C Kopp,
  10% owner
• Edward O Ii Lanphier,
  President and CEO
• Jon E M Jacoby,
  Director
• Casey C Case,
  Vice President, Research
• Peter Bluford,
  V.P., Corporate Development
• William J Rutter,
  Director
• John William Larson,
  Director
• Philip D Gregory,
  Vice President, Research
• Capital Management, L.P.Ra ...,
  
• David G Ichikawa,
  Senior VP, Bus. Dev.
• Jason D. Fontenot,
  SVP, Chief Scientific Officer
• Scott B. Willoughby,
  SVP, GEN. COUNSEL & SECRETARY
• Inc.Biogen Ma Inc. Biogen,
  
• Sandy Macrae,
  PRESIDENT, CEO AND DIRECTOR
• Nathalie Dubois Stringfellow,
  SVP-CHIEF DEVELOPMENT OFFICER
• Amy Pooler,
  VP, HEAD OF RESEARCH
• Courtney Beers,
  
• Margaret A Horn,